Tiefenbacher New Market Launch: Buprenorphine in Australia

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world. A key point here is that this applies to everyone, regardless of their nationality or income. That´s why we are thrilled to share that we have successfully prepared the launch of the generic version of the analgesic Buprenorphine as Transdermal Patch in Australia.

Affordable Medicines (fka Generics) are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

Buprenorphine belongs to a class of drugs known as opioid analgesics. Buprenorphine patches are used to help relieve severe and persistent pain (such as due to arthritis or chronic back pain). Our cooperation partner marketed the Transdermal Patches in the strengths 5mcg, 10mcg, 15mcg, and 20mcg. This product has already been launched in several international markets before.

The successful launch of this affordable medicine is a testament to the hard work and dedication of our team. We are particularly excited about the positive impact for the Australian healthcare system and look already forward to further market entries of our high-quality medicines.

Please click the highligthed words if you would like to know more about our product portfolio.